If your health care provider is prescribing semaglutide drugs, be sure to talk with them how you can adjust your diet so that it is sustainable over the long haul
Stempniewicz N, et al
Notably, these metabolic effects were uncoupled from changes in energy balance considerations, as food intake and weight gain remained unchanged
Because compounded semaglutide is not FDA-approved, the responsibility for quality falls on the pharmacy and the medical provider
Summary: Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) showing promising early evidence for significant weight reduction, improved metabolic markers, and reduced liver fat, but it has not yet received MHRA or EMA approval
doi:10.2337/dc10-2415 Fatty liver disease